The denitrosylating enzyme S-nitrosoglutathione reductase (GSNOR), has been reported to control the selective degradation of mitochondria through mitophagy, by modulating the extent of nitric oxide-modified proteins (S-nitrosylation). The accumulation of S-nitrosylated proteins due to GSNOR downregulation is a feature of hepatocellular carcinoma, causing mitochondrial defects that sensitize these tumors to mitochondrial toxins, in particular to mitochondrial complex II inhibitor alpha-tocopheryl succinate (αTOS). However, it is not known if mitophagy defects contribute to GSNOR-deficient cancer cells sensitivity to αTOS, nor if mitophagy inhibition could be used as a common mechanism to sensitize liver cancers to this toxin. Here, we provide evidence that GSNOR-deficient cancer cells show defective mitophagy. Furthermore, we show that αTOS is a mitophagy inducer and that mitophagy defects of GSNOR-deficient liver cancer cells contribute to its toxicity. We finally prove that the inhibition of mitophagy by depletion of Parkin, a pivotal ubiquitin ligase targeting mitochondria for degradation, enhances αTOS toxicity, thus suggesting that this drug could be effective in treating mitophagy-defective tumors.
Introduction
Mitophagy, the selective targeting of damaged mitochondria for lysosomal degradation, is an essential process controlling mitochondrial homeostasis. Being at the crossroads of metabolic, redox and cell death pathways, mitochondria play a central role in physiology and, not surprisingly, in several pathological settings, including cancer [1] [2] [3] . Although dysfunctional mitochondria are a feature of many malignancies, and contribute to the increased glycolytic metabolism referred as "Warburg effect" [4] [5] [6] , it is becoming clear that these organelles may also contribute to tumorigenesis by i) producing signaling molecules [7] [8] [9] ; ii) controlling Ca 2+ homeostasis [10] ; iii) acting as hub of cell death signals [11, 12] ; iv) catabolizing lipids and amino acids for energy production, or v) stimulating their de novo synthesis to generate biomass in proliferating cells [13, 14] . Due to these multiple roles, changes in the mitochondrial mass, which mostly derives from an imbalance between biogenesis and mitophagy, has been linked to both tumorigenesis and cell survival, as well as to tumor suppression [15] . Although mitophagy appears to be defective during cancer initiation, it acts mainly as a cytoprotective mechanism during cancer progression, as it supports cell survival under stressful conditions, e.g. nutrient deprivation or hypoxia [1] . From a clinical point of view, such a cytoprotective role can contribute to chemoresistance [16] [17] [18] . In support to this, BCL2-interacting protein 3 like (NIX)-dependent mitophagy has been identified as a process attenuating doxorubicin toxicity in colorectal cancer [19] . Similarly, the upregulation of ariadne RBR E3 ubiquitin protein ligase 1 (ARIH1) has been demonstrated to protect lung cancers from cisplatin by interacting with the mitochondrial potential sensor PTEN-induced kinase 1 (PINK1), and stimulating a Parkin-independent mitophagy [16] .
Several studies tested mitophagy inhibition as a method to enhance drugs sensitivity [20, 21] , and it has been suggested that selective silencing of mitophagy genes (e.g. PINK1 [16] , Parkin [22, 23] , BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, BNIP3 [24, 25] ), or the inhibition of lysosomes function (by chloroquine [26] , or the alkaloid liensinine [27] ) potentiates the antitumoral activity of conventional chemotherapeutics, e.g.
doxorubicin [27] , salinomycin [28] , paclitaxel and vincristine [29] . Notwithstanding this amount of data, to date, the use of specific mitophagy inhibitors is still far from being implemented in combined anticancer therapies.
We have recently demonstrated that the denitrosylase S-nitrosoglutathione reductase (GSNOR) indirectly regulates a set of proteins -such as Parkin [30, 31] -that are posttranslationally modified by nitric oxide (NO) through a reaction called S-nitrosylation [32, 33] . Parkin S-nitrosylation inhibits its capability to target damaged mitochondria for mitophagy degradation [34, 35] . As a result, cells in which GSNOR is downregulated are mitophagy-defective [30] .
GSNOR is a highly conserved enzyme that has been found downregulated in human hepatocellular carcinomas [36, 37] and breast cancer [38] . The etiological role of GSNOR in tumorigenesis is also confirmed by the evidence that GSNOR knock-out (KO) mice spontaneously develop liver cancer [36] . However, if this depends on mitophagy defects has not been investigated yet. In a previous work, we also demonstrated that GSNOR-KO cells show mitochondrial defects that can be exploited to selectively kill hepatocellular carcinoma cells [39] by the use of a class of mitochondrial drugs (named mitocans [40] ) directed to the Complex II of the mitochondrial respiratory chain (also known as succinate dehydrogenase, SDH).
Here we provide evidence that mitophagy is involved in the sensitivity of GSNOR-KO liver cancer cells to mitochondrial toxins, i.e. alpha-tocopheryl succinate (αTOS) [41] [42] [43] , suggesting the use of SDH-directed mitocans for the treatment of mitophagy-defective tumors.
Materials and Methods

Cell culture and treatments
HepG2 cell line was obtained from the Banca Biologica e Cell Factory (IRCCS AOU San Martino -IST Istituto Nazionale per la Ricerca sul Cancro). Huh-7 12 (HUH7) were purchased from Sigma-Aldrich. Both cell lines were grown in RPMI 1640 supplemented with 10% FBS and antibiotics at 37°C in an atmosphere of 5% CO 2 . All cell lines were cultured for fewer than 2 months after resuscitation and were used from the third to the fifteenth passage in culture. Cell lines validation was carried out by the producer by means of DNA Profile STR (Short Tandem Repeat) and mycoplasma contamination was routinely screened by a PCR-based assay. All the cell culture media and supplements were purchased from Gibco, Thermo-Fisher Scientific.
Compounds and concentrations used in the study are as follows: carbonyl cyanide mchlorophenyl hydrazone (CCCP, Sigma-Aldrich), 2.5-10 μM; chloroquine (CQ, Sigma-Aldrich), 20 μM; alpha-tocopheryl succinate (αTOS, Sigma-Aldrich), 40-60 μM. Incubation times are indicated in the figure legends.
Gene silencing
Transient knock down was performed by small interference RNA (siRNA) technique. Cell were transfected using RNAiMAX (Thermo Fisher Scientific) using endonuclease-prepared pools of siRNAs (esiRNA, Sigma-Aldrich) directed against GSNOR (siGSNOR) and Parkin (siParkin), or, as control, with a scramble siRNA duplex (siScr). HepG2 cells stably expressing eGFP-short-hairpin RNAs (shRNA) were generated in our lab with a procedure reported in [39] . 
Analysis of cell viability and cell death.
Immunofluorescence microscopy and analyses.
Cells were grown on cover slips preventively coated with Gelatin 1% in PBS (Sigma Aldrich), treated as indicated, washed twice in cold PBS and fixed with 4% paraformaldehyde (VWR) in PBS for 10 min at room temperature.
For mitochondrial dynamics analysis, cells were incubated with a permeabilization solution (PBS/Triton X-100 0.4% v/v), blocked for 1 h with a blocking solution (PBS/normal goat serum 10% v/v) and then incubated for 1 h with and anti-mitochondrial import receptor subunit TOM20 homolog (anti-TOM20 -sc-11415, Santa Cruz Biotechnology) antibody, or, alternatively, with an anti-heat shock protein A9 (anti-GRP75 -ADI-SPS-826, Enzo Life Sciences).
For the evaluation of mitophagy, cells were permeabilized in ice cold methanol (VWR) for 5 minutes, washed three times in PBS, incubated for 1 h in blocking solution and then over night with an anti-Microtubule-associated proteins 1A/1B light chain 3B (anti-LC3, 0231-100, Nanotools) and anti-TOM20 (Santa Cruz Biotechnology) antibodies. Cells were then washed twice with PBS and incubated for 1 h with fluorophore-conjugated secondary antibodies (AlexaFluor 488 and 568). Nuclei were stained with 1 μ g/ml Hoechst 33342 (Thermo-Fisher Scientific). Epifluorescence analysis was performed by using Delta Vision (Applied Precision) Olympus IX70 microscope. Confocal microscopy experiments were performed by using LSM800 microscope (ZEISS) equipped with an oil-immersion 63X objective and ZEN imaging software. Fluorescence images were adjusted for brightness, contrast and color balance by using Fiji [44] analysis software. Confocal microscopy images were deconvoluted using the software Huygens Professional (Scientific Volume Imaging).
3D-rendering of multi-stacks images was achieved by UCSF CHIMERA (Reagents of the University of California) [45] . Mitophagy rate was assessed upon incubation with 20 mM chloroquine, added 2 h before the end of the treatments to block mitochondria degradation within the autophagosomes. The percentage of mitochondria particles colocalizing with 
Protein determination.
Protein concentration was determined by the method of Lowry [46] .
Western blot.
Samples preparation and acquisition of Western blots were performed as previous reported [39] . Western blots shown are representative of at least n=3 independent experiments giving similar results. We used the following primary antibodies: anti- 
Statistical analyses.
Values are expressed as means ± SD (or SEM where specified) and statistical significance was assessed by Student's t-test using Prism 8.0 (GraphPad Software, Inc.) in order to determine which groups were significantly different from the others.
Results
GSNOR-deficient hepatocellular carcinoma cells show defective mitochondrial dynamics.
In order to study the effects of GSNOR-ablation on mitochondria in hepatocellular carcinoma, we took advantage of two different hepatoma cell lines: HUH7, in which we transiently knocked-down GSNOR by RNA interference, and HepG2, stably expressing eGFP-shRNAs targeting GSNOR (shGSNOR), or a non-target sequence (shScr) as a control. As shown in Figure 1A , neither transient nor stable GSNOR ablation affected the expression levels of nitric oxide synthase 2 (NOS) -the predominant NO-producing enzyme in HUH7 and HepG2 cells -and thioredoxin 1 (Trx1), which might complement lack of GSNOR denitrosylating activity induced by sh or siRNAs. These data suggest that no compensatory mechanisms are induced by GSNOR downregulation in our experimental conditions. However, as previously reported in murine neurons and fibroblasts [30, 31] , GSNOR knocking-down resulted in a marked decrease of mitochondrial transmembrane potential (ψ m ) ( Figure 1B) and a fragmentation of mitochondrial network (Figures 1C and D) . Overall, these data suggest that, in hepatocellular carcinoma cells, GSNOR deficiency results in mitochondrial fragmentation and depolarization.
GSNOR-deficient hepatocellular carcinoma cells show defective mitophagy.
We next investigated the effects of GSNOR downregulation on mitophagy, since this is a mechanism deeply impaired in condition of nitrosative stress induced by GSNOR decrease [30] . To this end, we treated HUH7 cells with the uncoupling agent CCCP, a well-known mitophagy inducer and evaluated mitochondrial mass upon MitoTracker Green staining as indirect measure of mitophagy. (Figure 2A) . Cytofluorometric assay indicated that CCCP induced a milder decrement of mitochondrial mass in siGSNOR than the control (siScr) counterpart, suggesting that mitochondrial removal was less efficient. To confirm these set of data, we performed live-imaging confocal microscopy analyses of HUH7 cells stained with Lysoracker Red (to follow lysosomes) and MitoTracker Green (to identify mitochondria). Results shown in Figure 2B (Movies 1-6) indicate that GSNOR-deficiency induced a defective recognition of mitochondria, strengthening the idea that mitophagy rate was compromised in siGSNOR cells. Accordingly, Western Blot analyses performed on HepG2 cells showed that the levels of three mitochondrial proteins commonly used as an estimation of mitochondrial mass (i.e. SDHA, VDAC and TOM20) were only slightly affected by CCCP in GSNOR-deficient conditions (shGSNOR) if compared with those measured in control counterparts (shScr) (Figure 2C) . Overall, these results suggest that loss of GSNOR impairs mitophagy in hepatocellular carcinoma cells.
GSNOR-deficient hepatocellular carcinoma cells are insensitive to αTOS-induced
mitophagy.
We previously demonstrated that, in hepatoma cells, GSNOR-deficiency is a condition associated with a rearrangement of the respiratory chain, namely the upregulation of complex II (succinate dehydrogenase, SDH) activity and oxygen consumption [39] , presumably as a mechanism to compensate the inhibition of complex I and IV. This feature provided the molecular rationale to the use of SDH-targeting mitochondrial toxins, exemplified by the vitamin E-derivative αTOS that, indeed, showed high (and selective) toxicity towards GSNOR-depleted cells [39] .
In the light of the results so far obtained, we wondered if αTOS was able to induce mitophagy and, further, if defects in mitophagy observed in GSNOR-deficient cells could contribute to their enhanced sensitivity towards this drug. To this end, we performed electron microscopy analyses of HepG2 cells treated with αTOS for 24 h and observed that mitochondrial ultrastructure was compromised. In particular, we noticed a decrease in the average mitochondrial size and in the number of mitochondrial cristae (Figure 3) in both shScr and shGSNOR cells. Interestingly, in shScr cells we noticed the presence of double-membraned structures surrounding the damaged organelles, presumably early autophagosomes. On the contrary, these structures were absent (or very rare) in GSNORdeficient cells treated with αTOS, notwithstanding mitochondria shape appeared severely compromised already in control (vehicle-treated) conditions. In order to confirm these results, we performed immunofluorescence analysis by labeling mitochondria with an anti-TOM20 antibody, and autophagosomes with an anti-LC3 antibody. To highlight mitophagy rate, this experiment was performed in the presence of chloroquine (CQ), a well-known inhibitor of lysosome acidification that blocks the degradation of autophagolysosomes content [47] . Fluorescence microscopy analyses indicated that αTOS was able to target mitochondria toward lysosomal degradation in siScr HUH7 cells, but not in GSNOR-deficient cells (Figure 4A) . Interestingly, the inability to trigger mitophagy was comparable to that observed in cells downregulating Parkin (siParkin) -the ubiquitin-ligase involved in targeting damaged mitochondria for degradation through mitophagy -that were selected as control (Figure 4A ). An estimation of mitophagy rate that gives the general idea of this phenomenon was provided in Figure 4B as unbiased count of the colocalization between anti-TOM20/anti-LC3 double positive particles. In line with these observations, we obtained similar results in HUH7 cells analyzed by live-imaging confocal microscopy, with αTOS treatment triggering mitophagy in siScr but not in siGSNOR cells (Figure 4C , Movies 7-12). Flow cytometry analyses were perfomed to quantify the decrease of mitochondrial mass, eventually confirming that siGSNOR cells retained more mitochondria upon αTOS treatment than the siScr counterpart (Figure 4D) , providing additional evidence that GSNOR-deficient cells were unable to remove αTOS-damaged mitochondria through selective autophagy.
Mitophagy impairment contributes to αTOS cytotoxicity.
We finally investigated the relationship between mitophagy and αTOS toxicity by analyzing cell death and survival upon GSNOR and/or Parkin downregulation (Figure 5A) in hepatocellular carcinoma cells. To this end, we treated HUH7 cells with αTOS for 24 h and evaluated cell death by combined staining with green-fluorescent calcein-AM (for living cells) and propidium iodide (for dead cells). Fluorescence microscopy analyses showed that GSNOR-deficient cells were more sensitive to αTOS cytotoxicity, confirming data previously obtained in our laboratory [39] (Figure 5B, C) . Interestingly, we also observed that Parkin downregulation enhanced αTOS-induced cell death in siScr cell, whereas it did not produce any additional effect in siGSNOR cells, arguing for a S-nitrosylation and Parkin laying on the same pathways. We then repeated the same experiment in HepG2 cells (Figure 5D ), confirming the same role of αTOS on cell viability in shGSNOR cells, where no further effects were observed in combination with siParkin ( Figure 5E) . This data suggested that, by sensitizing shScr cells to αTOS, Parkin silencing abolished the differences between GSNOR-deficient and proficient cells (Figure 5E) . We finally confirmed these results by Cristal Violet survival assay of cells treated for 4 days with αTOS. GSNOR downregulation as well as Parkin silencing resulted in a lower survival rate if compared with GSNOR-or Parkin-proficient (shScr or siScr) counterparts (Figure 5F) . In conclusion, these experiments reveal that it is possible to sensitize hepatocellular carcinoma cells to αTOS by inhibiting mitophagy. Moreover, our data suggest that Snitrosylation contributes to cell susceptibility to αTOS by a mitophagy-dependent mechanism, inasmuch Parkin does not, as these cells are already mitophagy defective (Figure 6 ).
Discussion
Mechanisms underlying mitophagy are currently under intense investigation as they represent potential therapeutic targets due to the cytoprotective role of this process in cancer. In this regard, it has been demonstrated that the efficiency in clearing up drugdamaged mitochondria attenuates, or even abolishes, treatment effectiveness in several chemotherapy settings [17, 20, 48] . Starting from this evidence, many research groups developed the idea of using mitophagy inhibitors to enhance the efficacy of conventional chemotherapies [21] . Similarly, the identification of mitophagy-defective cancer subtypes advocates the application of mitochondrial-targeting therapies designed to selectively affect cancer cells survival, avoiding mitophagy-proficient cells [21] . Interestingly, the main characterized mitophagy regulators, i.e. the PINK1/Parkin system, BNIP3 and NIX, have been shown to be downregulated in several cancer types [16, 25, [49] [50] [51] [52] , suggesting that these could be targets of mitochondrial-directed therapies.
It is commonly known that Parkin-null mice develop liver cancer spontaneously [51] .
Intriguingly, mice deficient for the denitrosylase GSNOR develop liver cancer as well [36, 53] , this pointing toward a common mechanism underlying tumorigenesis [54] . As a matter of fact, GSNOR-deficient cells show aberrant S-nitrosylation of Parkin, condition that compromises the E3-Ub ligase activity [34] and results in mitophagy defects [30] .
Supported by the findings of this work, it is reasonable to include GSNOR-deficient hepatocellular carcinoma among the mitophagy-defective cancers.
In addition, we recently demonstrated that, due to mitochondrial electron transport chain rearrangements, GSNOR-deficient liver cancers cells are particularly susceptible to the mitochondrial complex II-targeting drug αTOS [39, 41, 55] . We here expanded the knowledge about the mechanism of action of αTOS, demonstrating for the first time that this toxin induces mitophagy, and that, similarly to other chemotherapics, the removal of damaged mitochondria through mitophagy dampens its toxicity. These discoveries are in line with previous data indicating lysosome instability at the bases of αTOS-induced apoptosis [56] in solid tumors, in particular colorectal [56] and breast [57, 58] cancer. It is worth to note that breast cancer is actually characterized by GSNOR downregulation [38] .
However, whether mitophagy defects contribute to αTOS efficacy in breast cancer eradication still needs to be elucidated. More generally, the effectiveness of mitocans in the treatment of mitophagy-defective tumors is still neglected, even though it might represent an intriguing field of investigation.
In conclusion, in the present study, we propose the use of αTOS as a promising tool toward GSNOR-and Parkin-defective, as well as other mitophagy-deficient tumors, and provide a molecular rationale to predict tumor response to mitocans. 
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